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Abstract
Background: End-of-life cancer patients commonly receive more than one type of strong opioid. The three-step analgesic
ladder framework of the World Health Organisation (WHO) provides no guidance on multiple opioid prescribing and there is
little epidemiological data available to inform practice. This study aims to investigate the time trend of such cases and the
associated factors.
Methods: Strong opioid prescribing in the last three months of life of cancer patients were extracted from the General
Practice Research Database (GPRD). The outcome variable was the number of different types of prescribed non-rescue doses
of opioids (1 vs 2–4, referred to as a complex case). Associated factors were evaluated using prevalence ratios (PR) derived
from multivariate log-binomial model, adjusting for clustering effects and potential confounding variables.
Results: Overall, 26.4% (95% CI: 25.6–27.1%) of 13,427 cancer patients (lung 41.7%, colorectal 19.1%, breast 18.6%, prostate
15.5%, head and neck 5.0%) were complex cases. Complex cases increased steadily over the study period (1.02% annually,
95%CI: 0.42–1.61%, p = 0.048) but with a small dip (7.5% reduction, 95%CI: 20.03 to 17.8%) around the period of the
Shipman case, a British primary care doctor who murdered his patients with opioids. The dip significantly affected the
correlation of the complex cases with persistent increasing background opioid prescribing (weighted correlation
coefficients pre-, post-Shipman periods: 0.98(95%CI: 0.67–1.00), p = 0.011; 0.14 (95%CI: 20.85 to 0.91), p = 0.85). Multivariate
adjusted analysis showed that the complex cases were predominantly associated with year of death (PRs vs 2000: 1.05–
1.65), not other demographic and clinical factors except colorectal cancer (PR vs lung cancer: 1.24, 95%CI: 1.12–1.37).
Conclusion: These findings suggest that prescribing behaviour, rather than patient factors, plays an important role in
multiple opioid prescribing at the end of life; highlighting the need for training and education that goes beyond the well-
recognised WHO approach for clinical practitioners.
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Introduction
The reported prevalence of moderate to severe pain in
advanced cancer is approximately 64%, with a sharp increase to
as high as 80–90% at the end of life [1,2]. The traditional
mainstay of pain management since the 1980s has been the World
Health Organization (WHO) three-step ‘‘ladder’’ approach,
involving recommendation of a single strong opioid for moderate
to severe cancer pain [3,4]. However, increasingly over the
treatment course, patients may be switched (sometimes called
rotated) from one opioid to another because of side effects or
concerns regarding effectiveness of the initial opioid. In addition,
patients may be prescribed combinations of different opioids,
usually when they are receiving long acting and short acting
compounds or compounds by different routes, especially if one
compound is not available across the required formulations or
routes. Clinical management in such circumstances is more
complex, driven by patient’s response, and the need to have both
shorter and longer acting preparations and equianalgesic dose
ratios. The process of combining or switching opioids is more
complex for the clinician—as s/he must understand the different
half-life, receptors and conversion ratios of these opioids, which
can vary greatly between individuals, opioids and even by opioid
dose [5].
A patient being prescribed more than one type of strong opioid
(referred to here as a complex case) is a result of interplay between
various factors, which may involve disease-, socio-demographic,
healthcare practitioners- and health policy-related variables [6–
12]. Clinical observations found that around 10–30% of cancer
patients treated with oral morphine could not reach a balance
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between sufficient pain control and acceptable level of side effects
[13]. These patients need opioid switching or an opioid
combination to achieve optimal pain control. However, prescrib-
ing more than one type of strong opioid may not always mean that
there is a genuine clinical need; it may sometimes reflect
inadequate prescribing behaviour of physicians as discussed in a
review paper about physician-related barriers to cancer pain
management with opioid [14]. For example, in some situations,
adequate pain control could have been achieved by escalating the
dosage of the existing opioid therapy. The physician may fail to
increase doses due to fear of overdose; rather, s/he may choose an
alternative opioid at a low dose level. The use of adjuvants can
enhance the analgesic effect of opioid drugs in patients with cancer
[15]. Concurrent use of adjuvants is recommended by the WHO
and has been recognised as one of the effective strategies in
improving the balance between analgesia and side effects.
However, consistent evidence suggests an underutilisation of
adjuvants in cancer pain management, which may contribute to
unnecessary opioid switching or rotation [16]. For the reasons
discussed above, the term complex case is used here as an
indicator of complexity in managing cancer pain at the end of life,
although we appreciate that complexity in this context reflects
prescribing patterns, which may not be the ‘true’ clinical
complexity of the patients.
Studies concerning using opioids for pain relief in cancer
predominantly focused on factors affecting whether a patient
receives opioids or not. There is a scarcity of research on complex
cases in cancer pain management at the population level, more
specifically on: 1) time trends of complex cases, and 2) factors
associated with a patient being a complex case. The first question
has policy relevance, the second is imperative for early identifi-
cation of patients whose pain management will be genuinely
complex, to promote initiation of treatment geared towards best
management outcome of cancer pain. There is also no data on
whether patient related factors are playing a role in complex cases
or if it is predominantly related to healthcare practitioner’s
characteristics, prompting needs for education, training and even
policy-level interventions. Nevertheless, the information is partic-
ularly important for advanced cancer patients, to improve quality
of life in the last few months of life.
Data and Methods
Study design
A population-based, retrospective cohort study in primary care.
Data source
The study sample was extracted from the UK General Practice
Research Database (GPRD), the world’s largest primary care
research database. It covers a broadly representative 6% of the
UK population, and contains individual-level longitudinal data
from around 11 million patients registered with over 516 primary
care practices throughout the UK. It collects information on
demographics, diagnosis, prescribed medications, referrals and
almost all activities during GP consultations. The GPRD has set
up data quality standards to classify general practices with respect
to completeness, continuity, and plausibility of data recording. The
practices meet the quality standard are known as the ‘‘Up To
Standard’’ (UTS) practices [11,17].
Ethics statement
The analysis was based on fully anonymised data; therefore, no
ethical approval is required for this study.
Patient cohort
Inclusion criteria to select patients from the GPRD database
were:
1) A diagnosis of one of the most common primary cancers(lung,
colorectal, breast, prostate, head and neck), identified with
Read/OXMIS codes;
2) Died between 01/01/2000 and 31/12/2008;
3) Registered with an UTS GPRD practices for at least one year;
4) With at least one prescribing history of strong opioids in the
last three months of life.
Strong opioids
We reviewed the following fourteen types of strong opioids
which included those listed in the 4.7.2 BNF 6.1 and also those
available in the market during the study period: morphine,
diamorphine, fentanyl family(alfentanil, fentanyl,remifentanil),
oxycodone, buprenorphine, hydromorphone, methadone, others(-
dextromoramide, didipanone, papaveretum, pentazocine, pethi-
dine, tramadol, tapentadol).
Variables
The outcome variable was the number of different types of
strong opioids a patient received in the last three months of life.
This was calculated for each individual patient, by prospectively
tracking the prescriptions of strong opioids the patient received in
the last three months. ‘‘Rescue opioid’’ prescriptions were
excluded, because these were prescribed for prevention purpose
and patients may not actually use it [18]. The ‘‘rescue opioids’’
(short-acting or immediate release compound) was identified
whenever more than one type of strong opioids was prescribed
to a patient on the same date. Out of 68,023 prescriptions
containing one of the fourteen types of strong opioids, 6,451(9.5%)
were written at the same time, of which 2,701(41.9%) were ‘‘rescue
opioids’’.
The explanatory variables included: age at diagnosis, gender,
cancer site, year of death, opioid prescribing history in 3–6 months
prior to death, adapted Charlson co-morbidity score [19], social
economic status(SES) as measured by quintile of the index of
multiple deprivation(IMD, 0 = least deprived to 4 = most de-
prived), location of region where the practice with which patient
was registered. The number of non-opioid prescriptions a patient
received in the last three months and the survival time were
included as potential confounding variables.
Statistical analysis
Data was summarised using counts and percentages for
categorical variables, mean (SD) and median (range) for contin-
uous data. The 95% confidence interval (CI) of the percentage was
calculated using Wilson score method. The simple linear trend in
the percentage of patients who received more than one type of
strong opioid was explored using weighted piecewise linear
regression. We used log-binomial regression models to evaluate
which variables were associated with patients having received
more than one type of strong opioids. The outcome was modelled
as a binary variable (1 versus 2–4). The generalised estimation
equation (GEE) was used to account for the clustering effects
within practices. The explanatory variables were first tested in the
bivariate analysis using Chi-square test for their associations with
the outcome variable. Variables that were significant at the cut-off
p value of 0.20 were used to build multiple regression models, and
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the adjusted proportion ratios (APRs) were estimated from the
models.
All first-order interaction effects between factors showing
significant effect in multiple regression models were investigated.
We performed two sensitivity analyses to test the robustness of
the findings of the main analysis: 1) the percentage of the estimated
cost by GP prescribed opioids among all opioid prescriptions as an
additional adjusted variable, the analysis was restricted to the
England regions which have the data [20]; 2) analysis based on
patients without any referral records in the last three months - this
is in order to eliminate the potential impact by health care from
non-GP healthcare professionals or Step III opioid prescribing not
captured by the database.
A two-sided p value less than 0.05 was considered statistically
significant. Analyses were performed using SAS 9.3(SAS Institute,
Cary, North Carolina, USA).
Results
In total, 13,427 cancer patients with at least one prescribing
record of strong opioids in the last three months of life were
included in this study. It was a subset from a total of 29,847
patients with a diagnosis of one of the five major cancers,
excluding 37 patients with problematic (eg. year of death = 2500
or missing information on key variables (eg. date of diagnosis). The
median time to death after the last opioid prescription was 11 days
(Mean (SD): 17.9(19.2) days; range: 0–90 days). The median
number of non-opioid prescriptions patients received from their
GPs in the last three months was 24(Mean (SD): 28.1(21.2); range:
0–446).
Table 1 shows the socio-demographic and clinical characteris-
tics of the study population. Nearly 80% of those with at least one
prescribing history of strong opioids were aged over 60. There
were slightly more men than women (53.8% versus 46.2%). Two
in five (41.7%) patients in the study were lung cancer. The median
co-morbidity score was 3.0(Mean (SD): 4.6(2.9): range: 0–16), one
in three cancer patients (31.7%) were scored 6 or higher in the co-
morbidity index. Two thirds (66.2%) patients had no prescribing
history of strong opioids in 3–6 months before death. The study
sample consisted more of people who died in recent years (6.7% in
2000 to 15.3% and 12.9% in 2007 and 2008). Slightly more
people (SES 5: 24.0% versus 18.1% to 19.8% in other SES strata)
were from more deprived areas. Regions contributed differently to
the study sample in terms of number of patients (Northern Ireland
2.8% to Southern region 30.5%).
Over the 9-year period, 73.6% (95%CI: 72.9 to 74.4%), 23.2%
(95%CI: 22.4 to 23.9%), 3.0%(95%CI: 2.7 to 3.3%) of patients
received 1, 2 and 3 different types of strong opioids, respectively;
less than 0.2%(95%CI: 0.1 to 0.3%) patients received four types.
The proportion of complex cases according to our definition
increased steadily over the study period (1.02% annually, 95%CI:
0.42 to 1.61%). The proportion of patients who received more
than one type of strong opioid increased from 19.9%(95%CI: 17.4
to 22.6%) in 2000 to 29.4%(95%CI: 27.2 to 31.7%) in
2004(annual increase: 2.1%, 95%CI: 0.7 to 3.5%), followed by
small drops in 2005 and 2006 to 27.0%(95%CI: 25.0 to 29.1%);
the proportion rose again since 2007, to 29.7%(95%CI: 27.6 to
31.9%) in 2008; the annual increase was 0.2%(95%CI:20.8 to
1.2%) after 2004. The correlation between background opioid
prescribing and the proportion of complex cases was high
(weighted correlation coefficient (r): 0.82, 95%CI: 0.31 to 0.96,
p = 0.004) though differed by period: a nearly perfect correlation
before 2004(weighted r: 0.98, 95%CI: 0.67 to 1.00, p = 0.011) but
non-existent after 2004(weighted r: 0.14, 95%CI: 20.85 to 0.91,
p = 0.85). A piecewise regression analysis with one breakpoint at
2004 showed a satisfactory fit to the data (Fdf = 3 = 21.5, p = 0.003)
(Figure 1). The overall proportion of complex cases varied
narrowly by regions, ranging from the lowest 20.2% (95%CI:
20.2–25.1%) in London to the highest 27.3% (95%CI: 25.8–
28.8%) in North West and West Midlands.
Among those receiving two types of strong opioids (N = 3,113),
three common alternatives to morphine were diamorphine
(45.9%, 95%CI: 44.1–47.6%, fentanyl family (20.7%, 95%CI:
19.2–22.1%) and oxycodone (11.5%, 95%CI: 10.4–12.6%). For
those who had three types (N = 401), morphine, diamorphine and
fentanyl family together accounted for nearly half (45.6%, 95%CI:
40.8 to 50.5%). Only 25 patients were prescribed four types of
strong opioids in the last three months of life, 10 of them (40.0%,
95%CI: 20.8 to 59.2%) were prescribed morphine and its three
most common alternatives (diamorphine, fentanyl family and
oxycodone).
The bivariate association analysis identified 5 out of 8 candidate
variables for constructing the multiple regression model (Table 2).
The number of non-opioids prescriptions a patient received in the
last three months was included as a confounding variable
(significant in bivariate and multivariate analysis, both p
values,0.001). Only the statistical significance pertaining to
cancer site and year of death on the outcome was maintained in
multiple regression analysis. Compared with patients with lung
cancer, those with colorectal cancer (Adjusted PR: 1.25, 95%CI:
1.13 to 1.39) had higher chance of receiving more than one type of
strong opioid. The increasing trend in the chance of patients
receiving more than one type of strong opioids was confirmed in
the multivariate analysis: the adjusted PR versus reference year
(2000) rose to the peak in 2004(1.65, 95%CI: 1.36 to 2.01),
declined gradually thereafter, before climbing again to
1.66(95%CI: 1.35 to 2.04) in 2008. The two sensitivity analysis
showed similar results to those of main analysis (Table S1, S2).
The interaction effect between year of death and cancer site was
not significant (P = 0.35, X2df = 32 = 34.4).
Discussion
One of the main and interesting findings from this large-scale,
population-based longitudinal study is that the ‘‘year of death’’ is
the factor most strongly associated with being a complex case,
outweighing all other factors. Patients who died in more recent
years were more likely to receive more than one type of strong
opioids. The number of types of opioids prescribed to the patients
remained relatively stable during the study period, ranging from 8
in 1999 to 11 in 2000–2002 and 2006–2008. Over the years, the
under-treatment of pain in cancer patients has attracted consid-
erable attention [21]. Most barriers, reported in the literature, to
optimal pain management using opioids (ie. misconceptions of
patients, reluctance of physicians in prescribing) are concerned
with whether a patient receives opioids or not, rather than whether
patients have been prescribed more than one type of strong opioid.
This study therefore complements existing studies and examines
the patients who are already on opioid therapy [2,18]. However,
the barriers identified in the former may still influence dosage, type
and combination of opioids; and therefore, affect the chance of a
patient being a complex case. A systematic review identified a
problem that has not yet been widely researched, regarding the
role of the adequacy of opioid prescribing in cancer pain control
[14]. Two aspects of evidence arising from this study(as listed
below) also suggest that prescribing behaviour plays an important
role in patients receiving more types of strong opioids.
Managing Cancer Pain with Multiple Opioids
PLOS ONE | www.plosone.org 3 January 2014 | Volume 9 | Issue 1 | e79266
Firstly, the proportion of complex cases experienced a small
drop at 2005, it was coincident with the Shipman case that came
into full light following the suicide of this serial killer GP [22]. The
media coverage brought an unprecedented negative image on
strong opioids. A study conducted during the same period
demonstrated that the Shipman case made health professionals
Table 1. Demographic and clinical characteristics of cancer patients receiving at least one prescription of strong opioids at the
end of life, UK 2000–2008.
Variable Value Types of strong opioid prescribed in the last three months
1 2 3+ All
All 9888(73.6) 3113(23.2) 426(3.2) 13427(100.0)
Age ,50 779(7.9) 228(7.3) 40(9.4) 1047(7.8)
50–59 1411(14.3) 455(14.6) 74(17.4) 1940(14.4)
60–69 2526(25.5) 803(25.8) 120(28.2) 3449(25.7)
70–79 3121(31.6) 1000(32.1) 130(30.5) 4251(31.7)
80+ 2051(20.7) 627(20.1) 62(14.6) 2740(20.4)
Gender Female 4555(46.1) 1454(46.7) 198(46.5) 6207(46.2)
Male 5333(53.9) 1659(53.3) 228(53.5) 7220(53.8)
Cancer site Breast 1861(18.8) 554(17.8) 87(20.4) 2502(18.6)
Colorectal 1827(18.5) 647(20.8) 94(22.1) 2568(19.1)
Head and neck 490(5.0) 158(5.1) 29(6.8) 677(5.0)
Lung 4171(42.2) 1279(41.1) 150(35.2) 5600(41.7)
Prostate 1539(15.6) 475(15.3) 66(15.5) 2080(15.5)
Co-morbidity score 0–2 3197(32.3) 986(31.7) 154(36.2) 4337(32.3)
3–5 3608(36.5) 1097(35.2) 140(32.9) 4845(36.1)
6–8 1744(17.6) 567(18.2) 71(16.7) 2382(17.7)




No 6639(67.1) 2001(64.3) 244(57.3) 8884(66.2)
Yes 3249(32.9) 1112(35.7) 182(42.7) 4543(33.8)
Year 2000 726(7.3) 165(5.3) 15(3.5) 1669(12.4)
2001 860(8.7) 206(6.6) 24(5.6) 3795(28.3)
2002 908(9.2) 243(7.8) 32(7.5) 3484(25.9)
2003 979(9.9) 310(10.0) 36(8.5) 2090(15.6)
2004 1141(11.5) 412(13.2) 63(14.8) 2389(17.8)
2005 1265(12.8) 413(13.3) 60(14.1) 905(6.7)
2006 1299(13.1) 422(13.6) 59(13.8) 1090(8.1)
2007 1489(15.1) 486(15.6) 76(17.8) 1183(8.8)
2008 1221(12.3) 456(14.6) 61(14.3) 1325(9.9)
SES 1 (Least deprived) 1822(18.4) 643(20.7) 78(18.3) 1616(12.0)
2 1797(18.2) 556(17.9) 75(17.6) 1738(12.9)
3 1930(19.5) 633(20.3) 91(21.4) 1780(13.3)
4 1943(19.7) 551(17.7) 80(18.8) 2051(15.3)
5 (Most deprived) 2396(24.2) 730(23.5) 102(23.9) 1738(12.9)
Region EASTERN 1342(13.6) 424(13.6) 67(15.7) 2543(18.9)
LONDON 884(8.9) 237(7.6) 21(4.9) 2428(18.1)
NORTH EAST 815(8.2) 237(7.6) 28(6.6) 2654(19.8)
NORTH WEST AND WEST
MIDLAND
2453(24.8) 790(25.4) 131(30.8) 2574(19.2)
NORTHERN IRELAND 278(2.8) 91(2.9) 13(3.1) 3228(24.0)
SCOTLAND 597(6.0) 183(5.9) 25(5.9) 1883(14.0)
SOUTHERN 2986(30.2) 996(32.0) 115(27.0) 1142(8.5)
WALES 533(5.4) 155(5.0) 26(6.1) 1080(8.0)
doi:10.1371/journal.pone.0079266.t001
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more cautious of using strong opioids for treating pain [23]. Since
Dr Harold Shipman killed his patients through administering
overdose opioids [22], one would expect that the case would make
GPs overcautious in escalating opioid dose or switching to
alternative equi-analgesic opioids, even if there was a genuine
need of doing so. A recent qualitative study found professionals
working in primary care settings had particular concerns about
giving high doses opioids and felt incompetent in using opioids
[10].
Second, although the increase in complex cases may be
associated with the background opioid prescribing, easier access
or other factors, it only appeared to be true before the wake of the
Shipman case. A dramatic change (from perfect to none) in the
correlation between background opioid prescribing and the
complex cases was noted around the year of 2005. Patients and
their families often have concerns about initiating opioids, which
may impact whether a patient does or does not receive opioids.
Apparently, Shipman’s case did not affect the public’s perceptions
about opioids, as evident from the steady increase in patients
receiving opioid prescriptions [17]. However, after the initiation of
opioid therapy, it seems that GPs had more involvement in
managing or maintaining the therapy, and there may have been
more confusion about which opioid to prescribe in the face of
wider availability of different opioids and greater variety of routes
of administration.
This identified role of prescribing behaviour in complex cases
warrants further in-depth investigation. It may indicate prescribing
confusion or inadequacy or some other under-recognised
prescribing behaviour. It emphasizes the need for urgent training
and education to improve the knowledge and attitude of clinicians
about opioids (eg. reduced fear about life-limiting effects when
appropriately titrated).
We found that colorectal cancer patients had a higher chance of
being a complex case than patients with the other cancers. It may
be related to one of the most common side effects resulting from
using opioids - constipation. Although it is widely advised that the
concurrent use of laxatives and opioids, evidence suggests only a
minority of patients who were on strong opioids received laxatives
concomitantly [4,24,25]. The non-compliance to good prescribing
practices poses particular challenges for pain management in
cancers with pre-existing constipation, e.g. colorectal cancer.
Future work needs to examine how and to what extent suboptimal
prescribing leads to a patient having to switch unnecessarily.
Elderly cancer patients are less likely to receive analgesia than
their younger counterparts. Earlier research showed older age was
independently associated with the under-prescription for all levels
of analgesics [11]. Barriers to optimal pain relief may be more
common in older than in younger patients, which are mainly
related to misconceptions about opioids and disease [7]. However,
our data shows that once patients were on opioid therapies, there
was no evidence that pain management is more complex or
simpler in elderly patients. This is consistent with previous findings
[9].
Evidence is now emerging that there is an individual(patient by
patient) response to different opioids [26]. Searching for genetic or
disease specific modulators of this has so far proven unsuccessful
[27]. Current practice recommends switching if patients fail to
respond to an opioid, however, there is no evidence that one
switch is better than another. Some switches are more complex
than others [28,29]. Switching opioids or combining them requires
skilled clinicians who are aware of the latest evidence regarding
appropriate doses, as well a carefully monitoring during the switch
[26].
Nevertheless, over one in four cancer patients were complex
cases, beyond the WHO analgesic ladder. The increasing trend of
complex cases and the possible involvement of prescribing
practices in the process highlight the urgent need for further
investigation to clarify the role of prescribing behaviour and audit
opioid prescribing, as well as understand the effectiveness of opioid
switching, its mechanisms, and importantly equianalgesic dose
ratios. If it was prescribing inadequacy (especially if patients were
switched simply because they had not reached an effective dose
without side effects in the original opioid), then this prompts a
need for education and training [12,30,31]. The educational or
interventional programmes should target not only GPs, but also a
range of health professionals, who may play an even more
important role in initiating and maintaining opioid therapies
[10,31]. The education and training should go beyond the well-
Figure 1. Percentage (95% CI) of patients receiving more than one types of strong opioids in the last three months of life, England
2000–2008 (N = 13, 427). *A complex case refers to a patient being prescribed for more than one type of strong opioids in the last three months of
life.
doi:10.1371/journal.pone.0079266.g001
Managing Cancer Pain with Multiple Opioids
PLOS ONE | www.plosone.org 5 January 2014 | Volume 9 | Issue 1 | e79266
recognised WHO approach, and focus on issues of equi-analgesics
and safety, which are most challenging when converting from one
opioid to another or using opioids in combination.
Several limitations should be noted to interpret our findings.
First, the GPRD database only captures the opioids prescribed by
the GPs, we may miss some prescriptions through non-GP routes.
The likely impact of these ‘‘missed opioids’’ would be underesti-
mating the problem of the complex cases, which will strengthen
the need for educating and training health professionals. The
sensitivity analysis including the percentage of the GP prescribing
Table 2. Crude prevalence ratios (CPR, 95%CI) and adjusted prevalence ratios (APR, 95%CI)* of factors associated with the number
of type of strong analgesics a patient received in the last three months of life (N = 13,427).
Characteristics Value Crude PR
P value for overall
effects Adjusted PR
P value for Overall
effects
Age ,50 1.00 0.48 - -
50–59 1.10(0.92 to 1.30) - -
60–69 1.06(0.92 to 1.24) - -
70–79 1.05(0.91 to 1.22) - -
80+ 0.98(0.83 to 1.15) - -
Gender Male 1.00 0.51 - -
Female 1.03(0.95 to 1.11) - -
Cancer site Lung 1.00 0.022 1.00 ,0.001
Breast 1.00(0.90 to 1.11) 1.05(0.93 to 1.19)
Colorectal 1.17(1.06 to 1.30) 1.25(1.13 to 1.39)
Head & neck 1.11(0.93 to 1.33) 1.09(0.91 to 1.30)
Prostate 1.01(0.90 to 1.14) 0.96(0.85 to 1.10)
Co-morbidity score 0–2 1.00 0.21 - -
3–5 0.96(0.88 to 1.04) - -
6–8 1.02(0.92 to 1.14) - -
9–17 1.09(0.96 to 1.23) - -
Prescribing opioids in 3–6
months before death
No 1.00 ,0.001 1.00 0.05
Yes 1.18(1.08 to 1.29) 1.10((1.00 to 1.21)
Year of death 2000 1.00 ,0.001 1.00 ,0.001
2001 1.10(0.90 to 1.35) 1.05(0.86 to 1.29)
2002 1.25(1.00 to 1.56) 1.21(0.96 to 1.52)
2003 1.45(1.17 to 1.78) 1.42(1.15 to 1.75)
2004 1.72(1.42 to 2.09) 1.65(1.36 to 2.01)
2005 1.55(1.28 to 1.88) 1.46(1.20 to 1.77)
2006 1.54(1.26 to 1.89) 1.49(1.21 to 1.84)
2007 1.57(1.29 to 1.90) 1.44(1.18 to 1.75)
2008 1.77(1.44 to 2.16) 1.66(1.35 to 2.04)
SES 0 (least deprived) 1.00 0.08 1.00 0.09
1 0.88(0.76 to 1.03) 0.88(0.75 to 1.02)
2 0.93(0.81 to 1.08) 0.93(0.80 to 1.08)
3 0.81(0.70 to 0.94) 0.82(0.71 to 0.95)
4 (most deprived) 0.87(0.75 to 0.99) 0.86(0.74 to 0.99)
Region Southern 1.00 0.10 1.00 0.19
North east 0.88(0.76 to 1.03) 0.94(0.80 to 1.10)
Eastern 0.96(0.83 to 1.12) 0.99(0.85 to 1.15)
London 0.76(0.64 to 0.91) 0.79(0.66 to 0.95)
North west 0.99(0.87 to 1.13) 0.99(0.85 to 1.15)
Northern 1.00(0.80 to 1.25) 0.89(0.69 to 1.15)
Wales 0.91(0.74 to 1.10) 0.84(0.70 to 1.02)
Scotland 0.92(0.75 to 1.15) 0.90(0.72 to 1.14)
*CPRs and APRs were derived by using log-binomial models with the adjustment of correlation within practices. PRs greater than one indicate that the presence of the
characteristic confers higher risk of receiving more types of opioids.
doi:10.1371/journal.pone.0079266.t002
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in the multiple regression model did not substantially change the
main findings. Second, there is no data available to assess the
needs of pain relief and the effectiveness of the pain medications,
which are important for effective pain management. Though it is
reasonable to assume that those who were receiving opioid
prescriptions should be the group with high needs, we won’t be
able to judge the relationship between ‘‘more types of opioids’’ and
the outcome of pain treatment.
In conclusion, this large scale, population-based retrospective
cohort study found over one in four cancer patients were complex
cases; this showed an overall increasing trend but with a small dip
around the period of the Shipman case, a British primary care
doctor who murdered his patients with opioids. The dip
significantly affected the correlation of complex case with
persistent increasing background opioid prescribing. Multivariate
adjusted analysis also showed that complex cases were predom-
inantly associated with year of death, not other demographic and
clinical factors except colorectal cancer. These findings suggest
that prescribing behaviour, rather than patient factors, plays an
important role in multiple opioid prescribing at the end of life;
highlighting the need for training and education that goes beyond
the well-recognised WHO approach for clinical practitioners.
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